Chronic necrotizing pulmonary aspergillosis
Conditions
Interventions
Administration of antifungal drugs (MCFG)
Administration of antifungal drugs (VRCZ)
Sponsors
NEOCI (Nagasaki Evaluation Organization for CLinical Interventions)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients were eligible for enrolment if they were at least 20 years or older and diagnosed as CNPA. The diagnostic criteria for CNPA by Hope et al. with modification were used in this study. CNPA Patients fulfilled with following conditions; (1) existing al least one of symptom complex consisting of fever, weight loss, sputum, cough, hemoptysis, fatigue and shortness of breath. A criteria of CNPA was considered to be certain if it was associated with the following conditions; (2) New infiltrates or cavity formation or expansion of pre-existing cavities with or without peri-cavitary infiltrates and adjacent pleural thickening; (3) at least one positive result of serologic tests including Aspergillus antigen test, antibody test and/or any positive evidences if existence of Aspergillus species by molecular diagnosis, culture positive and pathological findings, (4) positive findings of at least one of the inflamation markers such as white blood cell (WBC) counts, value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), (5) non-improvement of symptoms to at least 3 days-administration of wide-broad antibiotics.
Exclusion criteria
Exclusion criteria: The following patients were excluded from the study: (1) patients received MCFG or VRCZ within a month at the time of the diagnosis of CNPA, (2) patients with simple aspergilloma, invasive pulmonary aspergillosis, or allergic bronchopulmonary aspergillosis, (3) patients with infectious diseases other than Aspergillosis, (4) pregnant patients, (5) patients without informed consent, and (6) patients with liver, kidney and heart failure (more than Grade II in CTCAEv3.0).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of drugs after administration of two weeks | — |
Countries
Japan
Contacts
Public ContactKoichi Izumikawa
Nagasaki University Graduate School of Biomedical Sciences Department of Molecular Microbiology and Immunology
Outcome results
None listed